New Lung Cancer Therapy May Target Previously Untreatable Tumors (Memorial Sloan Kettering Cancer Center)

Although some lung cancer patients have benefited from developments in precision therapy, those with mutations in a gene called KRAS have not. Now Memorial Sloan Kettering Cancer Center researchers are developing uses for a compound that targets a common KRAS mutation in lung cancer. Memorial Sloan Kettering Cancer Center is one of the 26 NCCN Member Institutions. ...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

In this study, we compared the long-term side effects of proton radiation to equivalent doses of X-rays in the initiation and progression of premalignant lesions in a lung cancer susceptible mouse model (K-rasLA1). We show proton irradiation causes more complex DNA damage that is not completely repaired resulting in increased oxidative stress in the lungs both acutely and persistently. We further observed K-rasLA1 mice irradiated with protons had an increased number and size of initiated and premalignant lesions and adenomas that were often infiltrated with inflammatory cells. Proton irradiated mice had a lower median surv...
Source: Life Sciences in Space Research - Category: Biology Source Type: research
Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling. Oncol Rep. 2018 Aug 02;: Authors: Zhang G, Fang T, Chang M, Li J, Hong Q, Bai C, Zhou J Abstract Gefitinib, an epidermal growth factor receptor (EGFR)‑specific drug, is effective for ~1 year, after which resistance is inevitable. Calpain 2 (CAPN2) is known to serve a role in the drug response and resistance in certain cancer therapies. However, the full function of CAPN2, particularly in non‑small cell lung cancer, has not yet be...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
i Kim Although many treatment strategies have been reported for lung disease, the mechanism of combination therapy using silver nanoparticles (AgNPs) and histone deacetylases inhibitors (HDACi) remains unclear. Therefore, innovative treatment strategies are essential for addressing the therapeutic challenges of this highly aggressive lung cancer. AgNPs and HDACi seem to be the best candidates for anticancer therapy because of their anti-proliferative effect in a variety of cancer cells. First, we synthesized AgNPs using wogonin as a reducing and stabilizing agent, following which the synthesized AgNPs were characterize...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Authors: Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA Abstract People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities. Lack of guidelines and provider education has le...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Authors: Hongtao L, Xiaoqi G, Junni L, Feng X, Guodong B, Liang Y Abstract Chlorogenic acid (CGA), an ester with various pharmacological effects, is important in cancer therapy. However, the specific antitumor mechanism of CGA is not entirely clear, especially with respect to its suppression of non-small cell lung cancer (NSCLC). The present study was carried out to assess the effect of CGA on NSCLC, and the mechanism involved. Cell viability assay and colony formation assay revealed that CGA blocked the proliferative capacity of NSCLC cells in vitro. Results from the migration assay suggested that CGA also inhibit...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Conclusion: Our results suggest that miR-125b-1-3p exerts antitumor functions in NSCLC cells by targeting S1PR1. PMID: 30082521 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
Abstract BMI-1 (B-lymphoma Mo-MLV insertion region 1) is a key protein partner in polycomb repressive complex 1 (PRC1) that helps in maintaining the integrity of the complex. It is also a key player in ubiquitination of histone H2A which affects gene expression pattern involved in various cellular processes such as cell proliferation, growth, DNA repair, apoptosis and senescence. In many cancers, Overexpression of BMI1correlates with advanced stages of disease, aggressive clinicopathological behavior, poor prognosis resistance to radiation and chemotherapy. BMI1 is emerging as a key player in EMT, chemo-resistance...
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
Authors: Rybarczyk-Kasiuchnicz A, Ramlau R Abstract Lung cancer is the main cause of cancer-related deaths in Poland. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a new group of agents for non-small-cell lung cancer (NSCLC) patients. Determining the predictive value of activating mutations in the EGFR and ROS-1 genes and ALK rearrangement in non-small-cell lung cancer has enabled the identification of patients likely to achieve true clinical benefits. EGFR-TKIs may produce objective response in more than 60% of patients and prolong progression-free survival to 10 months in mutation-posit...
Source: Polish Journal of Cardio-Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Kardiochir Torakochirurgia Pol Source Type: research
AbstractPurpose of ReviewLung cancer is increasingly a disease of the elderly. Historically, the information on how best to treat these patients is scant, but over recent years, there have been increasing data to support both systemic and targeted treatment as would be offered to younger patients. This paper aims to summarise the considerations behind this.Recent FindingsThe introduction of a screening tool to help understand the overall health of patients will ensure that older cancer patients are considered for all active anti-cancer therapies. These geriatric assessment tools include several important domains such as nu...
Source: Current Geriatrics Reports - Category: Geriatrics Source Type: research
ACS Chemical BiologyDOI: 10.1021/acschembio.8b00381
Source: ACS Chemical Biology - Category: Chemistry Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Lung Cancer